/wp-content/uploads/candel_logo.svg
0
0
cchan@candeltx.com
/wp-content/uploads/candel_logo.svg
cchan@candeltx.com2021-06-04 05:00:012021-06-03 16:51:49Candel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
/wp-content/uploads/candel_logo.svg
0
0
cchan@candeltx.com
/wp-content/uploads/candel_logo.svg
cchan@candeltx.com2021-05-27 05:00:092021-06-22 09:41:37Candel Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference
/wp-content/uploads/candel_logo.svg
0
0
cchan@candeltx.com
/wp-content/uploads/candel_logo.svg
cchan@candeltx.com2021-05-11 05:00:172021-06-22 09:41:18Candel Therapeutics Names Carrie S. Cox as Chairman of its Board of Directors
/wp-content/uploads/candel_logo.svg
0
0
cchan@candeltx.com
/wp-content/uploads/candel_logo.svg
cchan@candeltx.com2021-04-29 05:00:212021-06-22 09:40:55Candel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
/wp-content/uploads/candel_logo.svg
0
0
cchan@candeltx.com
/wp-content/uploads/candel_logo.svg
cchan@candeltx.com2021-04-22 05:14:122021-06-22 09:40:35Candel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo® (nivolumab) for the Treatment of High-Grade Gliomas
/wp-content/uploads/candel_logo.svg
0
0
cchan@candeltx.com
/wp-content/uploads/candel_logo.svg
cchan@candeltx.com2021-04-13 05:04:502021-06-22 09:40:14Candel Therapeutics Announces Formation of New Research Advisory Board Comprised of Multiple Prominent Scientists and Clinicians including 2018 Nobel Laureate, James Allison, Ph.D.
/wp-content/uploads/candel_logo.svg
0
0
cchan@candeltx.com
/wp-content/uploads/candel_logo.svg
cchan@candeltx.com2021-04-09 05:02:342021-06-22 09:39:18Candel Therapeutics Appoints Chris Matheny, PharmD, Ph.D., as Vice President, Development Leader
/wp-content/uploads/candel_logo.svg
0
0
David Anderson
/wp-content/uploads/candel_logo.svg
David Anderson2020-12-08 08:00:532020-12-08 08:00:53Candel Therapeutics Appoints Pharma Veteran and Immunologist Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer; Expands Leadership Team With Chief Financial Officer, Chief Business Officer and Chief Regulatory Officer Appointments
/wp-content/uploads/candel_logo.svg
0
0
David Anderson
/wp-content/uploads/candel_logo.svg
David Anderson2020-05-30 08:00:392020-05-30 08:00:39Candel Therapeutics Announces Presentation of Clinical Data for GMCI in NSCLC at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
/wp-content/uploads/candel_logo.svg
0
0
David Anderson
/wp-content/uploads/candel_logo.svg
David Anderson2020-05-18 08:00:012020-05-18 08:00:01Candel Therapeutics Announces Presentation at the 2020 American Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting
